细胞外基质降解系统在多发性肌炎发病机制中作用的实验研究
|
摘要
目的:
1制作理想的实验性自身免疫性肌炎动物模型;
2检测uPA、PAI-1、MMP-9、TIMP-2及肿瘤坏死因子-α在自身免疫性肌炎的肌肉组织中的表达,以探讨细胞外基质降解系统在多发性肌炎发病机制的重要作用。
方法:
1应用兔纯化的骨骼肌肌浆球蛋白(10mg/L)加完全弗氏佐剂4次皮下注射免疫豚鼠,同时联合腹腔注射百日咳杆菌原液(细菌数为4.0×10~(10)个/只),制作实验性自身免疫性肌炎模型;通过临床观察观测动物临床表现并采用LennonLA评分法评估动物病变程度,应用酶法测定动物血CK,应用HE染色技术观察不同动物的肌肉组织病理变化。
2采用逆转录PCR、实时定量PCR、免疫组织化学染色和Westernbloting方法检测正常组和EAM组豚鼠肌肉组织uPA、PAI-1、MMP-9、TIMP-2和TNF-alpha的基因mRNA及蛋白质表达。
3采用美国Graphpad Prism 4软件分析,各项指标以均数±标准差((?)±s)表示,对正常组和EAM组之间的计量资料进行t检验,P＜0.05表示差异有统计学意义。
结果:
1兔纯化的肌球蛋白加完全弗氏佐剂免疫豚鼠制作的动物模型的临床症状与病理改变与人类多发性肌炎类似;动物模型死亡率低,成功率高,病理改变典型。
2 uPA在正常组动物肌肉组织间质仅有微量表达,但在EAM组动物肌肉组织间质呈强阳性表达,尤其是,uPA在炎性细胞的胞膜、坏变肌纤维的胞膜与胞浆上呈明显强阳性表达,肌纤维的胞膜表达更为显著。PAI-1在正常组动物肌肉组织间质也仅有微量表达,在EAM组动物肌纤维间质、炎性细胞周围、坏变肌纤维呈强阳性表达。EAM组动物肌肉组织uPA与PAI-1基因mRNA及蛋白质表达的水平比正常组显著增高(P＜0.001),但其uPA/PAI-1基因mRNA表达的比例与正常组比较,则没有统计学差异(P＞0.05)。
3 MMP-9在正常组动物肌肉组织间质仅有微量表达,但在EAM组动物间质出现广泛强阳性表达,其在炎性细胞周围、坏变肌纤维的胞膜和胞浆有广泛表达,尤其胞膜表达最显著。TIMP-2在正常组和EAM组动物肌肉组织的毛细血管、静脉管壁、动脉内皮细胞和神经鞘膜均有表达,且EAM组的表达比正常组更明显,不过,TIMP-2在正常组和EAM组动物肌肉组织的肌内衣、外衣没有表达;但是,TIMP-2在正常组动物肌纤维的胞膜和胞浆没有表达,而在EAM组动物肌纤维的胞膜和胞浆有表达,但表达的范围不广泛。EAM组动物肌肉组织中MMP-9和TIMP-2基因mRNA及蛋白表达水平显著高于正常组(P＜=0.001),但EAM组MMP-9/TIMP-2基因mRNA表达的比例与正常组的表达有统计学差异(P＜0.001)。
4免疫组织化学染色发现TNF-alpha在正常组肌肉组织没表达,但在EAM组动物肌肉组织的坏变肌纤维胞膜和胞浆及周围的炎性细胞均有表达。EAM组动物肌肉组织TNF-α基因mRNA及蛋白表达水平均显著高于正常组(P＜0.001)。
结论
1兔纯化的肌球蛋白加含卡介苗的完全弗氏佐剂可仿制出人类多发性肌炎的理想动物模型。
2 UPA、PAI-1和TNF-α参与多发性肌炎的肌纤维坏变过程。
3 MMP-9和TIMP-2在正常肌肉组织中的毛细血管、静脉管壁、动脉肉皮细胞和神经鞘膜表达,在多发性肌炎中,参与加重肌纤维的坏变过程。
Objectives
1 To investigate the methods of inducing ideal experimental autoimmune myositis(EAM)animal model that mimic human polymyositis.
2 Evaluating the expression of the uPA、PAI-1、MMP-9、TIMP-2 and TNF-αin the EAM skeletal muscle in mRNA and protein level,to investigate the critical roles of extracellular matrix degregation system in the pathogenesis of PM.
Methods
1 EAM animal model was induced by pure rabbit myosin(10mg/l)mixed with CFA injected subcutaneously in guinea pigs,associated with bacillus pertussis(4.0×10~(10))injected intraperitoneally.We evaluated the model in clinical feature,the values of creatine kinase and pathological changes by LennonLA score,enzymic method and H&E staining technique.
2 RT-PCR,Westen blot analysis and immunohistochemistry stain were used to evaluate the expression of u-PA,PAI-1,MMP-9,TIMP-2,TNF-αmRNA and protein in the skeletal muscle of the normal and EAM groups.
3 The data were analyzed by Graphpad Prism 4 software.Comparison of data, presented as the mean±SD,was performed using t-test as indicated,p＜0.05 was considered significantly different.
Results
1 The clinical findings and pathologic changes in guinea pigs induced by pure Rabbit myosin mixed with CFA injected subcutaneously were similar to the human's idiopathic inflammatory myopathy.The mortality of the models was low and achievement ratio was high.The changes in pathology were typical.
2 The levels of the uPA and PAI-1 protein and mRNAs were increased significantly in the skeletal muscle of EAM guinea pigs compared with the levels in normal group.The ratio uPA to PAI-1 of transcriptional upregulation in the skeletal muscle was non-significant different between two groups,uPA and PAI-1 immunoreactivity were absent or weak in the skeletal muscle mesenchyma in normal group,but were significantly increased in EAM group. uPA and PAI-1 were strongly expressed in the degenerated,atrophic and necrotic fibers with or without inflammatory cells,and in the tissue space around the inflammatory cells in EAM muscle.
3 The levels of MMP-9,TIMP-2 protein and mRNAs in the skeletal muscle of EAM guinea pigs were increased significantly compared with the levels observed in the normal controls.In EAM muscle,MMP-9 is strongly expressed in the degenerated,atrophic,necrotic fibers with or without inflammatory cells, and in the tissue space around the inflammatory cells.TIMP-2 also expressed in the diseased muscle that MMP-9 immune was positive,but the less immunoreactivity range was observed compared with MMP-9.TIMP-2 immunoreactivity was positive in the capillary,venous wall,arteriola endotheliocyte in the both groups skeletal muscle,but more intensive in EAM.
4 The expression of TNF-αmRNA and protein was significantly up-regulated in the EAM muscle compared with the normal group.TNF-αimmunoreactivity were absent in the normal muscle,but were markedly up-regulated in the degenerated,necrotic,atrophy muscle fiber and around the inflammatory cells in the EAM muscle.
Conclusion
1 The EAM animal model induced by pure myosin mixed with CFA was similar to human's polymyositis.It was considered an effective and ideal model of PM.
2 uPA,PAI-1 and TNF-αwere all involved in the pathogenesis of PM and participated in the process of the degeneration,apoptosis and necrosis of the diseased muscle.
3 MMP-9 and TIMP-2 immunoreactivity were positive in the capillary,venous wall,arteriola endotheliocyte and neurilemma in the normal group skeletal muscle,but more intensive in EAM.They may aggravate the pathological changes of the muscle in human PM.
1制作理想的实验性自身免疫性肌炎动物模型;
2检测uPA、PAI-1、MMP-9、TIMP-2及肿瘤坏死因子-α在自身免疫性肌炎的肌肉组织中的表达,以探讨细胞外基质降解系统在多发性肌炎发病机制的重要作用。
方法:
1应用兔纯化的骨骼肌肌浆球蛋白(10mg/L)加完全弗氏佐剂4次皮下注射免疫豚鼠,同时联合腹腔注射百日咳杆菌原液(细菌数为4.0×10~(10)个/只),制作实验性自身免疫性肌炎模型;通过临床观察观测动物临床表现并采用LennonLA评分法评估动物病变程度,应用酶法测定动物血CK,应用HE染色技术观察不同动物的肌肉组织病理变化。
2采用逆转录PCR、实时定量PCR、免疫组织化学染色和Westernbloting方法检测正常组和EAM组豚鼠肌肉组织uPA、PAI-1、MMP-9、TIMP-2和TNF-alpha的基因mRNA及蛋白质表达。
3采用美国Graphpad Prism 4软件分析,各项指标以均数±标准差((?)±s)表示,对正常组和EAM组之间的计量资料进行t检验,P＜0.05表示差异有统计学意义。
结果:
1兔纯化的肌球蛋白加完全弗氏佐剂免疫豚鼠制作的动物模型的临床症状与病理改变与人类多发性肌炎类似;动物模型死亡率低,成功率高,病理改变典型。
2 uPA在正常组动物肌肉组织间质仅有微量表达,但在EAM组动物肌肉组织间质呈强阳性表达,尤其是,uPA在炎性细胞的胞膜、坏变肌纤维的胞膜与胞浆上呈明显强阳性表达,肌纤维的胞膜表达更为显著。PAI-1在正常组动物肌肉组织间质也仅有微量表达,在EAM组动物肌纤维间质、炎性细胞周围、坏变肌纤维呈强阳性表达。EAM组动物肌肉组织uPA与PAI-1基因mRNA及蛋白质表达的水平比正常组显著增高(P＜0.001),但其uPA/PAI-1基因mRNA表达的比例与正常组比较,则没有统计学差异(P＞0.05)。
3 MMP-9在正常组动物肌肉组织间质仅有微量表达,但在EAM组动物间质出现广泛强阳性表达,其在炎性细胞周围、坏变肌纤维的胞膜和胞浆有广泛表达,尤其胞膜表达最显著。TIMP-2在正常组和EAM组动物肌肉组织的毛细血管、静脉管壁、动脉内皮细胞和神经鞘膜均有表达,且EAM组的表达比正常组更明显,不过,TIMP-2在正常组和EAM组动物肌肉组织的肌内衣、外衣没有表达;但是,TIMP-2在正常组动物肌纤维的胞膜和胞浆没有表达,而在EAM组动物肌纤维的胞膜和胞浆有表达,但表达的范围不广泛。EAM组动物肌肉组织中MMP-9和TIMP-2基因mRNA及蛋白表达水平显著高于正常组(P＜=0.001),但EAM组MMP-9/TIMP-2基因mRNA表达的比例与正常组的表达有统计学差异(P＜0.001)。
4免疫组织化学染色发现TNF-alpha在正常组肌肉组织没表达,但在EAM组动物肌肉组织的坏变肌纤维胞膜和胞浆及周围的炎性细胞均有表达。EAM组动物肌肉组织TNF-α基因mRNA及蛋白表达水平均显著高于正常组(P＜0.001)。
结论
1兔纯化的肌球蛋白加含卡介苗的完全弗氏佐剂可仿制出人类多发性肌炎的理想动物模型。
2 UPA、PAI-1和TNF-α参与多发性肌炎的肌纤维坏变过程。
3 MMP-9和TIMP-2在正常肌肉组织中的毛细血管、静脉管壁、动脉肉皮细胞和神经鞘膜表达,在多发性肌炎中,参与加重肌纤维的坏变过程。
Objectives
1 To investigate the methods of inducing ideal experimental autoimmune myositis(EAM)animal model that mimic human polymyositis.
2 Evaluating the expression of the uPA、PAI-1、MMP-9、TIMP-2 and TNF-αin the EAM skeletal muscle in mRNA and protein level,to investigate the critical roles of extracellular matrix degregation system in the pathogenesis of PM.
Methods
1 EAM animal model was induced by pure rabbit myosin(10mg/l)mixed with CFA injected subcutaneously in guinea pigs,associated with bacillus pertussis(4.0×10~(10))injected intraperitoneally.We evaluated the model in clinical feature,the values of creatine kinase and pathological changes by LennonLA score,enzymic method and H&E staining technique.
2 RT-PCR,Westen blot analysis and immunohistochemistry stain were used to evaluate the expression of u-PA,PAI-1,MMP-9,TIMP-2,TNF-αmRNA and protein in the skeletal muscle of the normal and EAM groups.
3 The data were analyzed by Graphpad Prism 4 software.Comparison of data, presented as the mean±SD,was performed using t-test as indicated,p＜0.05 was considered significantly different.
Results
1 The clinical findings and pathologic changes in guinea pigs induced by pure Rabbit myosin mixed with CFA injected subcutaneously were similar to the human's idiopathic inflammatory myopathy.The mortality of the models was low and achievement ratio was high.The changes in pathology were typical.
2 The levels of the uPA and PAI-1 protein and mRNAs were increased significantly in the skeletal muscle of EAM guinea pigs compared with the levels in normal group.The ratio uPA to PAI-1 of transcriptional upregulation in the skeletal muscle was non-significant different between two groups,uPA and PAI-1 immunoreactivity were absent or weak in the skeletal muscle mesenchyma in normal group,but were significantly increased in EAM group. uPA and PAI-1 were strongly expressed in the degenerated,atrophic and necrotic fibers with or without inflammatory cells,and in the tissue space around the inflammatory cells in EAM muscle.
3 The levels of MMP-9,TIMP-2 protein and mRNAs in the skeletal muscle of EAM guinea pigs were increased significantly compared with the levels observed in the normal controls.In EAM muscle,MMP-9 is strongly expressed in the degenerated,atrophic,necrotic fibers with or without inflammatory cells, and in the tissue space around the inflammatory cells.TIMP-2 also expressed in the diseased muscle that MMP-9 immune was positive,but the less immunoreactivity range was observed compared with MMP-9.TIMP-2 immunoreactivity was positive in the capillary,venous wall,arteriola endotheliocyte in the both groups skeletal muscle,but more intensive in EAM.
4 The expression of TNF-αmRNA and protein was significantly up-regulated in the EAM muscle compared with the normal group.TNF-αimmunoreactivity were absent in the normal muscle,but were markedly up-regulated in the degenerated,necrotic,atrophy muscle fiber and around the inflammatory cells in the EAM muscle.
Conclusion
1 The EAM animal model induced by pure myosin mixed with CFA was similar to human's polymyositis.It was considered an effective and ideal model of PM.
2 uPA,PAI-1 and TNF-αwere all involved in the pathogenesis of PM and participated in the process of the degeneration,apoptosis and necrosis of the diseased muscle.
3 MMP-9 and TIMP-2 immunoreactivity were positive in the capillary,venous wall,arteriola endotheliocyte and neurilemma in the normal group skeletal muscle,but more intensive in EAM.They may aggravate the pathological changes of the muscle in human PM.
引文
1.韩顺昌,蒲传强。英夫利昔治疗实验性免疫性肌炎的实验研究。中国神经免疫学神经病学杂志.2007;6:336-339.
2.Kojima T,Tanuma N,Aikawa Y,et al.Myosin-induced autoimmune polymyositis in the rat.J Neurol Sci,1997;151:141-148.
3.Rosenberg NL,Ringel SP,Kotzin BL.Experimental autoimmune myositis in SJL/J mice,1987,68:117-129
4.Constantinescu CS,Hilliard B,Fujioka T,et al.Pathogenesis of neuroimmunologic diseases.Experimental models.Immunol.Res.1998,17:217-227.
5.Wada J,Shintani N,Kikutani K,et al.Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.Clin Exp Immunol.2001;124(2):282-9
6.Matsubara S,Shima T,Takamori M.Experimental allergic myositis in SJL/J mice immunized with rabbit myosin B fraction:immunohistochemical analysis and transfer.Acta Neuropathol(Berl).1993;85(2):138-44
7.张宁,肖波,李静等.实验性自身免疫性肌炎中MMP-2,MMP-9,TIMP-1的表达及甲基强的松龙的影响.湖南医科大学学报,2003;28(1):5-8.
8.徐宝林,江新梅,杨蕴天.豚鼠实验变应性肌炎的药物干预治疗及肌肉病理研究.中风与神经疾病杂志,2007,24(4):471-4.
9.Nemto H,Bhopale MK,Constantinescu CS,et al.Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis.Exp Mol Pathol,2003;74;238-243.
10.Kohayama K,Matsumoto Y.C-protein in the skeletal muscle induces severe autoimmune myositis in Lewis rats.J Neuroimmunol,1999,98:130-135.
l.Adair-Kirk TL,Senior RM.Fragments of extracellular matrix as mediators of inflammation.Int J Biochem Cell Biol.2008;40(6-7):1101-10.
2.Ram M,Sherer Y,Shoenfeld Y.Matrix metalloproteinase-9 and autoimmune diseases.J Clin Immunol.2006;26(4):299-307.
3.Birkedal-Hansen H,Moore WG,Bodden MK,et al.Matrix metalloproteinases:a review.Crit Rev Oral Biol Med.1993;4(2):197-250.
4.Nagase H,Woessner JF Jr.Matrix metalloproteinases.J Biol Chem.1999 30;274(31):21491-4.
5.Dass K,Ahmad A,Azmi AS,Sarkar SH,Sarkar FH.Evolving role of uPA/uPAR system in human cancers.Cancer Treat Rev.2008;34(2):122-36.
6.Killeen S,Hennessey A,El Hassan Y et al.The urokinase plasminogen activator system in cancer:a putative therapeutic target.Drug News Perspect.2008;21(2):107-16.
7.Vassalli JD,Sappino AP,Belin D.The plasminogen activator/plasmin system.J Clin Invest.1991;88(4):1067-72.
8.Judex MO,Mueller BM.Plasminogen activation/plasmin in rheumatoid arthritis:matrix degradation andmore.Am J Pathol.2005;166(3):645-7.
9.Li J,Ny A,Leonardsson G,Nandakumar KS et al.The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type Ⅱ-induced arthritis.Am J Pathol.2005;166(3):783-92.
10.Kim TD,Song KS,Li G et al.Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.BMC Cancer.2006;6:211.
11 Crippa MP.Urokinase-type plasminogen activator.Int J Biochem Cell Biol.2007;39(4):690-4.
12 Owen CA.Leukocyte cell surface proteinases:regulation of expression,functions,and mechanisms of surface localization.Int J Biochem Cell Biol.2008;40(6-7):1246-72.
13 Carmeliet P,Moons L,Dewerchin M et al.Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998;140(1):233-45.
14.Menshikov M,Elizarova E,Plakida K et al.Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis.Biochem J.2002;367(Pt 3):833-9.
15.Carlin SM,Resink TJ,Tamm M et al.Urokinase signal transduction and its role in cell migration.FASEB J.2005;19(2):195-202.
16.Shushakova N,Eden G,Dangers M et al.The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung.J Immunol.2005;175(6):4060-8.
17.Gyetko MR,Aizenberg D,Mayo-Bond L.Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro.J Leukoc Biol.2004;76(3):648-56.
18.Sitrin RG,Shollenberger SB,Strieter RM et al.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
19.J,Du X,Witte DP,Jirouskova M et al.Leukocyte engagement of fibrin(ogen)via the integrin receptor alphaMbeta2/Mac-l is critical for host inflammatory response in vivo.J Clin Invest.2004;113(11):1596-606.
20.Smiley ST,King JA,Hancock WW.Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4.J Immunol.2001;167(5):2887-94.
21.Lluis F,Roma J,Suelves M et al.Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo.Blood.2001;97(6):1703-11.
22.Lluri G,Jaworski DM.Regulation of TIMP-2,MT1-MMP,and MMP-2 expression during C2C12 differentiation.Muscle Nerve.2005;32(4):492-9.
23.Bryer SC,Fantuzzi G,Van Rooijen N,et al.Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.J Immunol.2008;180(2):1179-88.
24 Binder BR,Mihaly J,Prager GW.uPAR-uPA-PAI-1 interactions and signaling:a vascular biologist's view.Thromb Haemost.2007;97(3):336-42.
25 Sitrin RG,Shollenberger SB,Strieter RM et al.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
26.Rossignol P,Luttun A,Martin-Ventura JL et al.Plasminogen activation:a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.J Thromb Haemost.2006;4(3):664-70.
27 Margaret A.Gyetko,Susan B.Shollenberger,and Robert G.Sitrin.Urokinase expression in mononuclear hagocytesxytokine-specific modulation by interferon-y and tumor necrosis factor-a J.Leukoc.Biol.,1992;31:256-263;
28 St(?)bgen JP.Tumor necrosis factor-alpha antagonists and neuropathy.Muscle Nerve.2008 Mar;37(3):281-92.
29 Feliciani C,Toto P,Wang B,et al.Urokinase plasminogen activator mRNA is induced by IL-1 alpha and TNF-alpha in in vitro acantholysis.Exp Dermatol.2003;12(4):466-71.
30 Ma LJ,Fogo AB.PAI-1 and kidney fibrosis.Front Biosci.2009;14:2028-41.
31 Roelofs JJ,Teske GJ,Bonta PI et al.Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis.Kidney Int.2009;75(1):52-9.Epub 2008 Sep 17.
32.Aso Y.Plasminogen activator inhibitor (PAI)-l in vascular inflammation and thrombosis.Front Biosci.2007;12:2957-66.
33.Andreasen PA.PAI-1-a potential therapeutic target in cancer.Curr Drug Targets.2007;8(9):1030-41.
34 Koh TJ,Bryer SC,Pucci AM et al.Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration.Am J Physiol Cell Physiol.2005;289(1):C217-23.
35 Cao C,Lawrence DA,Li Y et al.Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.EMBO J.2006 3;25(9):1860-70.
36 Czekay RP,Aertgeerts K,Curriden SA et al.Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.J Cell Biol.2003;160(5):781-91.
37.Onwuegbusi BA,Rees JR,Lao-Sirieix P et al.Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.PLoS ONE.2007;2(1):e177.
38 Arndt PG,Young SK,Worthen GS.Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway.J Immunol.2005;175(6):4049-59.
39.Marshall LJ,Ramdin LS,Brooks T et al.Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes.J Immunol.2003;171(4):2057-65.
40.Kwak SH,Wang XQ,He Q et al.Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway.Thromb Haemost.2006;95(5):829-35.
42.Arndt PG,Young SK,Worthen GS.Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway.J Immunol.2005;175(6):4049-59.
43.Balsara RD,Ploplis VA.Plasminogen activator inhibitor-1:the double-edged sword in apoptosis.Thromb Haemost.2008;100(6):1029-36.
44.Schneider DJ,Chen Y,Sobel BE.The effect of plasminogen activator inhibitor type 1 on apoptosis.Thromb Haemost.2008;100(6):103 7-40.
45.Lademann UA,R0mer MU.Regulation of programmed cell death by plasminogen activator inhibitor type 1(PAI-1).Thromb Haemost.2008;100(6):1041-6.
46.Park YJ,Liu G,Lome EF et al.PAI-1 inhibits neutrophil efferocytosis.Proc Natl Acad Sci USA.2008;105(33):11784-9.
47.Nagamine Y.Transcriptional regulation of the plasminogen activator inhibitor type 1—with an emphasis on negative regulation.Thromb Haemost.2008;100(6):1007-13.
1.Nagase H,Visse R,Murphy G.Strucrure and function of matrix metalloproteinases and TIMPs.Cardiovasc Res.2006;69(3):562-73.
2.Carmeli E,Moas M,Reznick Az et al.Matrix metalloproteinases and skeletal muscle:a brief review.Muscle Nerve.2004;29(2):191-7.
3.Malla N,SJ0li S,Winberg JO et al.Biological and pathobiological functions of gelatinase dimers and complexes.Connect Tissue Res.2008;49(3):180-4.
4.Nagase H,Woessner JF Jr.Matrix metalloproteinases.J Biol Chem.1999;274(31):21491-4.
5.Birkedal-Hansen H,Moore WG,Bodden MK,et al.Matrix metalloproteinases:a review.Crit Rev Oral Biol Med.1993;4(2):197-250.
6.Ram M,Sherer Y,Shoenfeld Y.Matrix metalloproteinase-9 and autoimmune diseases.J Clin Immunol.2006;26(4):299-307.
7.Balcerzak D,Querengesser L,Dixon WT,Baracos VE.Coordinate expression of matrix-degrading proteinases and their activators and inhibitors in bovine skeletal muscle.J Anim Sci.2001;79(1):94-107.
8.Kim WU,Min SY,Cho ML,et al.Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.Arthritis Res Ther.2005;7(1):R71-9.
9.Muroski ME,Roycik MD,Newcomer RG et al.Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis.Curr Pharm Biotechnol.2008;9(1):34-46.
10.Kieseier BC,Schneider C,Clements JM,et al.Expression of specific matrix metalloproteinases in inflammatory myopathies.Brain.2001;124(Pt 2):341-51.
11.Choi YC,Dalakas MC.Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.Neurology.2000 11;54(1):65-71.
12.Fukushima K,Nakamura A,Ueda H,et al.Activation and localization of matrix metalloproteinase-2 and-9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ).BMC Musculoskelet Disord.2007;8:54.
13.Wiendl H,Hohlfeld R,Kieseier BC.Immunobiology of muscle:advances in understanding an immunological microenvironment.Trends Immunol.2005;26(7):373-80.
14.Delclaux C,Delacourt C,D'Ortho MP,et al.Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane.Am J Respir Cell Mol Biol.1996;14(3):288-95.
15.Tani K,Ogushi F,Shimizu T,et al.Protease-induced leukocyte chemotaxis and activation:roles in host defense and inflammation.J Med Invest.2001;48(3-4):133-41.
16.Gong Y,Hart E,Shchurin A,et al.Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice.J Clin Invest.2008;118(9):3012-24.
17.Mott JD,Werb Z.Regulation of matrix biology by matrix metallopro-teinases.Curr Opin Cell Biol.2004;16(5):558-64.
18.Visse R,Nagase H.Matrix metalloproteinases and tissue inhibitors of metallopro-teinases:structure,function,and biochemistry.Circ Res.2003;92(8):827-39.
19.Stetler-Stevenson WG.Tissue inhibitors of metalloproteinases in cell signaling:metalloproteinase-independent biological activities.Sci Signal.2008;l(27):re6.
20.Fernandez CA,Butterfield C,Jackson G,et al.Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2):loop 6 is a novel angiogenesis inhibitor.J Biol Chem.2003;278(42):40989-95.
21.von Moers A,Zwirner A,Reinhold A,et al.Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and-2 inDuchenne muscular dystrophy.ActaNeuropathol.2005;109(3):285-93.
22.Srivastava AK,Qin X,Wedhas N,et al.Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAKl)-dependent signaling pathway.J Biol Chem.2007;282(48):35113-24.
23.Liu Z,Li N,Diaz LA,Shipley M,et al.Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.J Clin Invest.2005;115(4):879-87.
24.Stetler-Stevenson WG,Seo DW.TIMP-2:an endogenous inhibitor of angiogenesis.Trends Mol Med.2005;11(3):97-103.
25.Stetler-Stevenson WG.The tumor microenvironment:regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2.Cancer Metastasis Rev.2008;27(1):57-66.
26.English JL,Kassiri Z,Koskivirta I,et al.Individual Timp deficiencies differentially impact pro-MMP-2 activation.J Biol Chem.2006;281 (15):10337-46.
27.Bernardo MM,Fridman R.TIMP-2 (tissue inhibitor of metalloproteinase-2)regulates MMP-2 (matrix metalloproteinase-2)activity in the extracellular environm-ent after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.Biochem J.2003 Sep 15;374(Pt 3):739-45.
28.Lluri G,Langlois GD,Soloway PD,et al.Tissue inhibitor of metalloproteinase-2 (TIMP-2)regulates myogenesis and betal integrin expression in vitro.Exp Cell Res.2008;314(1):11-24.
29.Gomez DE,Alonso DF,Yoshiji H,et al.Tissue inhibitors of metalloproteinases:structure,regulation and biological functions.Eur J Cell Biol.1997 Oct;74(2):l 11-22.
30.Murphy AN,Unsworth EJ,Stetler-Stevenson WG.Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation.J Cell Physiol.1993;157(2):351-8.
31.Rao BG.Recent developments in the design of specific Matrix Metalloproteinase inhibitorsaided by structural and computational studies.Curr Pharm Des.2005;l l(3):295-322.
1.Rider LG,Gurley RC,Pandey JP et al.Clinical,serologic,and immunogenetic features of familial idiopathic inflammatory myopathy.Arthritis Rheum.1998;41(4):710-9.
2.Mastaglia FL,Phillips BA.Idiopathic inflammatory myopathies:epidemiology,classification,and diagnostic criteria.Rheum Dis Clin North Am.2002;28(4):723-41.
3.Shamim EA,Rider LG,Miller FW.Update on the genetics of the idiopathic inflammatory myopathies.Curr Opin Rheumatol.2000;12(6):482-91.
4.Dalakas MC.Therapeutic targets in patients with inflammatory myopathies:present approaches and a look to the future.Neuromuscul Disord.2006;16(4):223-36.
5.Labioche I,Liozon E,Weschler B,et al.Refractory polymyositis responding to infliximab:extended follow-up.Rheumatology (Oxford).2004;43(4):531-2.
6.Hengstman G,van den Hoogen FHJ,Van egelen B,et al.Anti-TNF blockade with infliximab(Remicade)in polymyositis and dermatomyositis.Arthritis Rheum,2000;43:s193.
7.Sprott H,Glatzel M,Michel BA.Treatment of myositis with etanercept (Enbrel),a recombinant human solublefusion protein of TNF-alpha type Ⅱ receptor and IgGl.Rheumatology (Oxford).2004;43(4):524-6.
8.Uthman I,El-Sayad J.Refractory polymyositis responding to infliximab.Rheumatology (Oxford).2004;43(9):1198-9.
9.Concstantine K,Saadeh A.Etanercept is effective in treatment of polymyositis/dermatomyositis which is refractory to convestional therapy including steroid and other disease modifying agents.Arthritis Rheum,2000;43:s193
10.Hengstman GJ,van den Hoogen FH,Barrera P et al.Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha:preliminary observations.Eur Neurol.2003;50(1):10-5.
11.Pachman LM,Liotta-Davis MR,Hong DK et al.TNFalpha-308A allele in juvenile dermatomyositis:association with increased production of tumor necrosis factor alpha,disease duration,and pathologic calcifications.Arthritis Rheum.2000;43(10):2368-77.
12.Lutz J,Huwiler KG,Fedczyna T,et al.Increased plasma thrombospondin-1(TSP-1)levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis.Clin Immunol.2002;103(3Pt1):260-3.
13.刘继峰,许爱娥,杜晓航等.肿瘤坏死因子基因多态性与多发性肌炎与皮肌炎的相关性分析.中华风湿病学杂志,2005,9(7):397-400.
14 Royuela M,Rodr(?)guez-Berriguete G,Fraile B et al.TNF-alpha/IL-1/NFkappaB transduction pathway in human cancer prostate.Histol Histopathol.2008;23(10):1279-90.
15.Popa C,Netea MG,van Riel PL,et al.The role of TNF-alpha in chronic inflammatory conditions,intermediary metabolism,and cardiovascular risk.J Lipid Res.2007;48(4):751-62.
16 Ackermann C,Kavanaugh A.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Expert Opin Ther Targets.2007;11(11):1369-84.
17.Efthimiou P.Tumor necrosis factor-alpha in inflammatory myopathies:pathophy-siology and therapeutic implications.Semin Arthritis Rheum.2006;36(3):168-72.
18.Kuru S,Inukai A,Kato T,Liang Yet al.Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and noninflammatory myopathies.Acta Neuropathol.2003;105(3):217-24.
19 Kuru S,Inukai A,Liang Y,Doyu M et al.Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis.Acta Neuropathol.2000;99(5):585-8.
20.Tateyama M,Nagano I,Yoshioka Met al.Expression of tumor necrosis factor-alpha in muscles of polymyositis.J Neurol Sci.1997;146(1):45-51.
21 Gyetko MR,Shollenberger SB,Sitrin RG.Urokinase expression in mononuclear phagocytes:cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.J Leukoc Biol.1992;51(3):256-63.
22 Stubgen JP.Tumor necrosis factor-alpha antagonists and neuropathy.Muscle Nerve.2008;37(3):281-92.
23 Feliciani C,Toto P,Wang B et al.Urokinase plasminogen activator mRNA is induced by IL-1 alpha and TNF-alpha in in vitro acantholysis.Exp Dermatol.2003;12(4):466-71.
24.Peiretti F,Bernot D,Lopez S,et al.Modulation of PAI-1 and proMMP-9 syntheses by soluble TNFalpha and its receptors during differentiation of the human monocytic HL-60 cell line.J Cell Physiol.2003;196(2):346-53.
25 Zhou L,Yan C,Gieling RG et al.Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated Kinase-1.BMC Immunol.2009;10(1):15.
26.Yang WL,Godwin AK,Xu XX.Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells:molecular basis linking ovulation and cancer risk.Cancer Res.2004;64(4):1534-40.
27.Kieseier BC,Schneider C,Clements JM et al.Expression of specific matrix metalloproteinases in inflammatory myopathies.Brain.2001;124(Pt 2):341-51.
28 Choi YC,Dalakas MC.Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.Neurology.2000 11;54(1):65-71.
29 Schoser BG,Blottner D,Stuerenburg HJ.Matrix metalloproteinases in inflammatory myopathies:enhanced immunoreactivity near atrophic myofibers.Acta Neurol Scand 2002,105(4):309-313.
30 Malla N,Sjoli S,Winberg JO et al.Biological and pathobiological functions of gelatinase dimers and complexes.Connect Tissue Res.2008;49(3):180-4.
31 Gabay C,Gay-Croisier F,Roux-Lombard P et al.Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis.A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.Arthritis Rheum 1994;37(12):1744-51.
32.Shimizu T,Tomita Y,Son K,Nishinarita S,Sawada S,Horie T.Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.Clin Rheumatol 2000;19(5):352-9.
33 Min JK,Kim YM,Kim SW,et al.TNF-related activation-induced cytokine enhances leukocyte adhesiveness:induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells.J Immunol.2005;175(1):531-40.
34.Moser B,Wolf M,Walz A,et al.Chemokines:multiple levels of leukocyte migration control.Trends Immunol.2004;25(2):75-84.
35.Lykouras D,Sampsonas F,Kaparianos A,et al.Role and pharmacogenomics of TNF-alpha in asthma.Mini Rev Med Chem.2008;8(9):934-42.
36.Phillips T,Leeuwenburgh C.Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction.FASEB J.2005;19(6):668-70.
37.Dirks AJ,Leeuwenburgh C.Tumor necrosis factor alpha signaling in skeletal muscle:effects of age and caloric restriction.J Nutr Biochem.2006;17(8):501-8.
38 Sitrin RG,Shollenberger SB,Strieter RM,Gyetko MR.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
39 Jackson JM.TNF-alpha inhibitors.J.Dermatol Ther.2007;20(4):251-64.
40 Gao Q,Meijer MJ,Schliiter UG et al.Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and-9 in Crohn's disease.Inflamm Bowel Dis.2007;13(6):693-702.
1.Melchor JP,Strickland S.Tissue plasminogen activator in central nervous system physiology and pathology.Thromb Haemost.2005;93(4):655-60.
2.Killeen S,Hennessey A,El Hassan Y,Waldron B.The urokinase plasminogen activator system in cancer:a putative therapeutic target? Drug News Perspect.2008;21(2):107-16.
3.Li J,Ny A,Leonardsson G,Nandakumar KS et al.The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type Ⅱ-induced arthritis.Am J Pathol.2005;166(3):783-92.
4.Judex MO,Mueller BM.Plasminogen activation/plasmin in rheumatoid arthritis:matrix degradation and more.Am J Pathol.2005;166(3):645-7.
5.Crippa MP.Urokinase-type plasminogen activator.Int J Biochem Cell Biol.2007;39(4):690-4.
6.Tang CH,Wei Y.The urokinase receptor and integrins in cancer progression.Cell Mol Life Sci.2008;65(12):1916-32.
7.Vassalli JD,Sappino AP,Belin D.The plasminogen activator/plasmin system.J Clin Invest.1991;88(4):1067-72.
8.Owen CA.Leukocyte cell surface proteinases:regulation of expression,functions,and mechanisms of surface localization.Int J Biochem Cell Biol.2008;40(6-7):1246-72.
9 Carmeliet P,Moons L,Dewerchin M,et al.Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998;140(1):233-45.
10.Liu Z,Li N,Diaz LA,et al.Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.J Clin Invest.2005;115(4):879-87.
11.Binder BR,Mihaly J,Prager GW.uPAR-uPA-PAI-1 interactions and signaling:a vascular biologist's view.Thromb Haemost.2007;97(3):336-42.
12.Carmeliet P,Moons L,Dewerchin M et al.Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998 12;140(1):233-45.
13.Rossignol P,Luttun A,Martin-Ventura JL et al.Plasminogen activation:a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.J Thromb Haemost.2006;4(3):664-70.
14.Horowitz JC,Rogers DS,Simon RH et al.Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis.Am J Respir Cell Mol Biol.2008;38(1):78-87.
15.Carlin SM,Resink TJ,Tamm M,et al.Urokinase signal transduction and its role in cell migration.FASEB J.2005;19(2):195-202.
16.Bryer SC,Fantuzzi G,Van Rooijen N et al.Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.J Immunol.2008;180(2):1179-88.
17 Gyetko MR,Aizenberg D,Mayo-Bond L.Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro.J Leukoc Biol.2004;76(3):648-56.
18.Sitrin RG,Shollenberger SB,Strieter RM et al.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
19.Shushakova N,Eden G,Dangers M et al.The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung.J Immunol.2005;175(6):4060-8.
20.Hoyer-Hansen G,Lund IK.Urokinase receptor variants in tissue and body fluids.Adv Clin Chem.2007;44:65-102.
21.Plesner T,Behrendt N,Ploug M.Structure,function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor,uPAR.Stem Cells.1997;15(6):398-408.
22 Llinas P,Le Du MH,Gardsvoll H et al.Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.EMBO J.2005 4;24(9):1655-63.
23.Olson LJ,Yammani RD,Dahms NM et al.Structure of uPAR,plasminogen,and sugar-binding sites of the 300 kDa mannose 6-phosphate receptor.EMBO J.2004;23(10):2019-28.
24 Roelofs J J,Teske GJ,Bonta PI et al.Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis.Kidney Int.2009;75(1):52-9.
25.Cao C,Lawrence DA,Li Y et al.Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.EMBO J.2006;25(9):1860-70.
26.Cale JM,Lawrence DA.Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.Curr Drug Targets.2007;8(9):971-81.
27.Marshall LJ,Ramdin LS,Brooks T et al.Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes.J Immunol.2003;171(4):2057-65.
28.Kwak SH,Wang XQ,He Q et al.Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway.Thromb Haemost.2006;95(5):829-35.
29.Degryse B,Neels JG,Czekay RP et al.The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.J Biol Chem.2004;279(21):22595-604.
30 Arndt PG,Young SK,Worthen GS.Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway.J Immunol.2005;175(6):4049-59.
31.Balsara RD,Ploplis VA.Plasminogen activator inhibitor-1:the double-edged sword in apoptosis.Thromb Haemost.2008;100(6):1029-36.
32.Schneider DJ,Chen Y,Sobel BE.The effect of plasminogen activator inhibitor type 1 on apoptosis.Thromb Haemost.2008;100(6):1037-40.
33.Lademann UA,Romer MU.Regulation of programmed cell death by plasminogen activator inhibitor type l(PAI-l).Thromb Haemost.2008;100(6).T041-6.
[1].Hugues,S.M.,and Blau,H.M.Migration of myoblasts across basal lamina during skeletal muscle development.[J].Nature,1990,345:350-353.
[2].Shi,X.,and D.J.Garry.Muscle stem cells in development,regeneration,and disease.Genes Dev.2006.20:1692-1708.
[3].Munoz-Canoves P,Miralles F,Baiget M,and Felez J.Inhibition of urokinase-type plasminogen activator (uPA)abrogates myogenesis in vitro.Thromb Haemost 1997.77:526-534,
[4].Lluis,F.,J.Roma,M.Suelves,et al.Urokinase-dependentplasminogen activation is required for effi cient skeletal muscle regeneration in vivo.Blood.2001.97:1703-1711.
[5].Lopez-Alemany,R.,Suelve,M.,Munoz-Canoves,P.Plasmin generation dependent on a-enolase-type plasminogen receptor is required for myogenesis.Thromb Haemost.2003;90:724-33.
[6].M.Suelves,B.Vidal,A.L.Serrano,et al.uPA deficiency exacerbates muscular dystrophy in MDX mice J.Cell Biol.,September 7,2007;178(6):1039-1051.
[7].Carmeliet,and P.Munoz-Canoves.Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo.Blood.2002.99:2835-2844.
[8].Carmeliet P,Moons L,Dewerchin M.et al.Receptor independent role of urokinase-type activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998,140:233-245.
[9].Castellino FJ,Ploplis VA.Structure and function of the plasminogen/plasmin system.Thromb Haemost 2005;93:647-654.
[10].Blasi F,Carmeliet P.uPAR:a versatile signaling orchestrator.Nat Rev Mol Cell Biol.2002,3:932-943
[11].Ingber,D.Celluar tensegrity:defining new rules of biological design that govern the cytoskeleton.[J]Cell Sci.1993,104:613-627
[12].Kanse,S.M.,Kost,C.,Wilhelm,O.G.,et al.The urokinase receptor is a major vitronectin-binding protein on endothelial cells.Exp.Cell Res.1996.224:344-353.
[13].Waltz DA,Natkin LR,Fujita RM,Wei Y,and Chapman HA.Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.J Clin Invest.1997.100:58-67,
[14].Chazaud B,Bonavaud S,Plonquet A,et al.Involvement of the [uPAR:uPA:PAI-l:LRP]complex in human myogenic cell motility.Exp Cell Res 2000,258:237-244.
[15].Bonavaud,S.,Charriere-Bertrand,C.,Rey,C.,et al.Evidence of a non-conventional role for the urokinase tripartite complex in myogenic fusion.J.Cell Sci.1997,110:1083-1089
[16]Koh,T.J.,S.C.Bryer,A.M.Pucci,and T.H.Sisson.Mice defi cient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration.Am.J.Physiol.Cell Physiol.2005.289:C217-C223.
[17].Suelves,M.,B.Vidal,V.Ruiz,B.Baeza-Raja,A.Diaz-Ramos,I.Cuartas,F.Lluis,M.Parra,M.Jardi,R.Lopez-Alemany,et al.The plasminogen activation system in skeletal muscle regeneration:antagonistic roles of urokinase-type plasminogen activator (uPA)and its inhibitor (PAI-1).Front.Biosci.2005.10:2978-2985.
[18].Planus,E.,Barlovatz-Meimon,G.,Rogers,R.A.,et al.Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.J.Cell Sci.1997,110:1091-1098
[19]Kjoller,L.,Kanse,S.M.,Kirkegaard,T.,et al.plasminogen activator inhibitor type 1 represses integrin-and vitronectin-mediated cell migration independent of its function as an inhibitor of plasmingen activation.Exp Cell Res 1997,232:420-429.
[20]Tatsumi R,Anderson JE,Nevoret CJ,Halevy O,and Allen RE.HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells.Dev Biol.1998.194:114-128,
[21]Yablonka-Reuveni Z,Seger R,and Rivera AJ.Fibroblast growth factor promotes recruitment of skeletal muscle satellite cells in young and old rats.J Histochem Cytochem.1999.47:23-42,
[22]Mars WM,Zarnegar R,and Michalopoulos GK.Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.Am J Pathol.1993.143:949-958,
[23]Naldini L,Tamagnone L,Vigna E,Sachs M,Hartmann G,Birchmeier W,Daikuhara Y,Tsubouchi H,Blasi F,and Comoglio PM.Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.EMBO J.1992.11:4825-4833,
[24]Fibbi G,D'Alessio S,Pucci M,Cerletti M,and Del Rosso M.Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system.Biol Chem.2002.383:127-136,
[25]Arnold,L.,A.Henry,F.Poron,Y.Baba-Amer,N.van Rooijen,A.Plonquet,R.K.Gherardi,and B.Chazaud.Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis.J.Exp.Med.2007.204:1057-1069.
[26]Tidball,J.G.,and M.Wehling-Henricks.Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo.J.Physiol.2007.578:327-336.
[27]Bryer SC,Fantuzzi G,Van Rooijen N,Koh TJ.Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.J Immunol.2008.180(2):1179-88.
[28]D.M.DiPasquale,M.Cheng,W.Billich,S.A.Huang,N.van Rooijen,T.A.Hornberger,and T.J.Koh.Urokinase-type plasminogen activator and macrophages are required for skeletal muscle hypertrophy in mice.Am J Physiol Cell Physiol,2007;293(4):C1278-C1285.
[29]Sonnet,C,P.Lafuste,L.Arnold,M.Brigitte,F.Poron,F.J.Authier,F.Chretien,R.K.Gherardi,and B.Chazaud.Human macrophages rescue myoblasts and myotubes from apoptosis through a set of adhesion molecular systems.J.Cell Sci.2006.119:2497-2507.
[30]Luikart,S.,M.Masri,D.Wahl,T.Hinkel,J.M.Beck,M.R.Gyetko,P.Gupta,and T.Oegema.Urokinase is required for the formation of mactinin,an alpha-actinin fragment that promotes monocyte/macrophage maturation.Biochim.Biophys.Acta.2002.1591:99-107.
[31]Navaneetha K.Rao,Guo-Ping Shi,Harold A.Urokinase Receptor Is a Multifunctional Protein:Influence of ReceptorOccupancy on Macrophage Gene Expression.J.Clin.Invest.Volume,1995;96:465-474
[32]Margaret R.Gyetko,Robert F.Todd,Camille C.Wilkinson,et al.The Urokinase Receptor Is Required for Human Monocyte Chemotaxis In Vitro.J.Clin.Invest.1994.93:1380-1387.
[33]Scott C.Bryer,Timothy J.Koh.The urokinase-type plasminogen activator receptor is not required for skeletal muscle inflammation or regeneration.Am J Physiol Regul Inter Comp Physiol.2007.293:R1152-1158.
1.Carswell EA,Old LJ,Kassel RL et al.An endotoxin-induced serum factor that causes necrosis of tumors.Proc Natl Acad Sci USA.1975;72(9):3666-70.
2.Medzhitov R,Janeway C Jr.Innate immunity.N Engl J Med.2000 Aug 3;343(5):338-44.
3.Royuela M,Rodriguez-Berriguete G,Fraile B,et al.TNF-alpha/IL-1/NF-κB transduction pathway in human cancer prostate.Histol Histopathol.2008 Oct;23(10):1279-90.
4.Brightling C,Berry M,Amrani Y.Targeting TNF-alpha:a novel therapeutic approach for asthma.J Allergy Clin Immunol.2008;121(1):5-10;quiz 11-2.
5.Mease PJ,Kivitz AJ,Burch FX et al.Etanercept treatment of psoriatic arthritis:safety,efficacy,and effect on disease progression.Arthritis Rheum.2004;50(7):2264-72.
6.Srübgen JP.Tumor necrosis factor-alpha antagonists and neuropathy.Muscle Nerve.2008;37(3):281-92.
7.Sprott H,Glatzel M,Michel BA.Treatment of myositis with etanercept (Enbrel),a recombinant human soluble fusion protein of TNF-alpha type Ⅱ receptor and IgGl.Rheumatology (Oxford).2004;43(4):524-6.
8.Uthman I,El-Sayad J.Refractory polymyositis responding to infliximab.Rheumatology (Oxford).2004;43(9):1198-9.
9.Concstantine K,Saadeh A.Etanercept is effective in treatment of polymyositis/dermatomyositis which is refractory to convestntional therapy including steroid and other disease modifying agents.Arthritis Rheum,2000;43:s193
10.Hengstman GJD,van den Hoogen FHJ,Barrera P et al.Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis.European Neurology;2003;50(1):10-15
11.Cazzola M,Polosa R.Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma.Curr Opin Allergy Clin Immunol.2006;6(1):43-50.
12.Lykouras D,Sampsonas F,Kaparianos A,Karkoulias K et al.Role and pharmacogenomics of TNF-alpha in asthma.Mini Rev Med Chem.2008;8(9):934-42.
13.Popa C,Netea MG,van Riel PL et al.The role of TNF-alpha in chronic inflammatory conditions,intermediary metabolism,and cardiovascular risk.J Lipid Res.2007;48(4):751-62.
14 Ackermann C,Kavanaugh A.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Expert Opin Ther Targets.2007 Nov;11(11):1369-84.
15.Hatano E.Tumor necrosis factor signaling in hepatocyte apoptosis.J Gastroenterol Hepatol.2007;22 Suppl 1:S43-4.
17 Cope A,Ettinger R,McDevitt H.The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire.Res Immunol.1997;148(5):307-12.
18.Cope AP,Liblau RS,Yang XD,Congia M,Laudanna C,Schreiber RD,Probert L,Kollias G,McDevitt HO.Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling.J Exp Med.1997;185(9):1573-84.
19.Hughes G,Murphy MP,Ledgerwood EC.Mitochondrial reactive oxygen species regulate the temporal activation of nuclear factor kappaB to modulate tumour necrosis factor-induced apoptosis:evidence from mitochondria-targeted antioxidants.Biochem J.2005;389(Pt 1):83-9.
20 Li JM,Fan LM,Christie MR et al.Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells:role of p47phox phosphorylation and binding to TRAF4.Mol Cell Biol.2005;25(6):2320-30.
21.Kieseier BC,Kiefer R,Gold R et al.Advances in understanding and treatment of immune-mediated disorders of theperipheral nervous system.Muscle Nerve.2004;30(2):131-56.
22 Min JK,Kim YM,Kim SW et al.TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells.J Immunol.2005;175(1):531-40.
23.Moser B,Wolf M,Walz A et al.Chemokines:multiple levels of leukocyte migration control.Trends Immunol.2004;25(2):75-84.
24.Yang WL,Godwin AK,Xu XX.Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells:molecular basis linking ovulation and cancer risk.Cancer Res.2004;64(4):1534-40.
25.Zhou L,Yan C,Gieling RG et al.Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated Kinase-1.BMC Immunol.2009;10(1):15.
26.Peiretti F,Bernot D,Lopez S,Bonardo B et al.Modulation of PAI-1 and proMMP-9 syntheses by soluble TNFalpha and its receptors during differentiation of the human monocytic HL-60 cell line.J Cell Physiol.2003;196(2):346-53.
27 Feliciani C,Toto P,Wang B et al.Urokinase plasminogen activator mRNA is induced by IL-1 alpha and TNF-alpha in in vitro acantholysis.Exp Dermatol.2003;12(4):466-71.
28.Gyetko MR,Shollenberger SB,Sitrin RG.Urokinase expression in mononuclear phagocytes:cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.J Leukoc Biol.1992;51(3):256-63.
29.Kuru S,Inukai A,Kato T,et al.Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies.Acta Neuropathol,2003,105(3):217-24.
30 Kuru S,Inukai A,Liang Y,et al.Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis.Acta Neuropathol.2000;99(5):585-8.
31.Tateyama M,Nagano I,Yoshioka M,et al.J Neurol Sci.Expression of tumor necrosis factor-alpha in muscles of polymyositis.1997,146(1):45-51.
32.Efthimiou P.Tumor necrosis factor-alpha in inflammatory myopathies:pathophysiology and therapeutic implications.Semin Arthritis Rheum.2006;36(3):168-72.
33 Dirks AJ,Leeuwenburgh C.Tumor necrosis factor alpha signaling in skeletal muscle:effects of age and caloric restriction.J Nutr Biochem.2006;17(8):501-8.
35.Le Magueresse-Battistoni B,Pernod G,Kolodie L et al.Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rattesticular peritubular cells.Endocrinology.1997;138(3):1097-105.
36.Lopez S,Peiretti F,Bonardo B et al.Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells.J Biol Chem.2000;275(5):3081-7.
37.Bauer S,Pollheimer J,Hartmann J et al.Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures.J Clin Endocrinol Metab.2004;89(2):812-22.
38.Park YJ,Liu G,Lome EF et al.PAI-1 inhibits neutrophil efferocytosis.Proc Natl Acad Sci USA.2008;105(33):11784-9.
39.Jackson JM.TNF-alpha inhibitors.J.Dermatol Ther.2007;20(4):251-64.
2.Kojima T,Tanuma N,Aikawa Y,et al.Myosin-induced autoimmune polymyositis in the rat.J Neurol Sci,1997;151:141-148.
3.Rosenberg NL,Ringel SP,Kotzin BL.Experimental autoimmune myositis in SJL/J mice,1987,68:117-129
4.Constantinescu CS,Hilliard B,Fujioka T,et al.Pathogenesis of neuroimmunologic diseases.Experimental models.Immunol.Res.1998,17:217-227.
5.Wada J,Shintani N,Kikutani K,et al.Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.Clin Exp Immunol.2001;124(2):282-9
6.Matsubara S,Shima T,Takamori M.Experimental allergic myositis in SJL/J mice immunized with rabbit myosin B fraction:immunohistochemical analysis and transfer.Acta Neuropathol(Berl).1993;85(2):138-44
7.张宁,肖波,李静等.实验性自身免疫性肌炎中MMP-2,MMP-9,TIMP-1的表达及甲基强的松龙的影响.湖南医科大学学报,2003;28(1):5-8.
8.徐宝林,江新梅,杨蕴天.豚鼠实验变应性肌炎的药物干预治疗及肌肉病理研究.中风与神经疾病杂志,2007,24(4):471-4.
9.Nemto H,Bhopale MK,Constantinescu CS,et al.Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis.Exp Mol Pathol,2003;74;238-243.
10.Kohayama K,Matsumoto Y.C-protein in the skeletal muscle induces severe autoimmune myositis in Lewis rats.J Neuroimmunol,1999,98:130-135.
l.Adair-Kirk TL,Senior RM.Fragments of extracellular matrix as mediators of inflammation.Int J Biochem Cell Biol.2008;40(6-7):1101-10.
2.Ram M,Sherer Y,Shoenfeld Y.Matrix metalloproteinase-9 and autoimmune diseases.J Clin Immunol.2006;26(4):299-307.
3.Birkedal-Hansen H,Moore WG,Bodden MK,et al.Matrix metalloproteinases:a review.Crit Rev Oral Biol Med.1993;4(2):197-250.
4.Nagase H,Woessner JF Jr.Matrix metalloproteinases.J Biol Chem.1999 30;274(31):21491-4.
5.Dass K,Ahmad A,Azmi AS,Sarkar SH,Sarkar FH.Evolving role of uPA/uPAR system in human cancers.Cancer Treat Rev.2008;34(2):122-36.
6.Killeen S,Hennessey A,El Hassan Y et al.The urokinase plasminogen activator system in cancer:a putative therapeutic target.Drug News Perspect.2008;21(2):107-16.
7.Vassalli JD,Sappino AP,Belin D.The plasminogen activator/plasmin system.J Clin Invest.1991;88(4):1067-72.
8.Judex MO,Mueller BM.Plasminogen activation/plasmin in rheumatoid arthritis:matrix degradation andmore.Am J Pathol.2005;166(3):645-7.
9.Li J,Ny A,Leonardsson G,Nandakumar KS et al.The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type Ⅱ-induced arthritis.Am J Pathol.2005;166(3):783-92.
10.Kim TD,Song KS,Li G et al.Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.BMC Cancer.2006;6:211.
11 Crippa MP.Urokinase-type plasminogen activator.Int J Biochem Cell Biol.2007;39(4):690-4.
12 Owen CA.Leukocyte cell surface proteinases:regulation of expression,functions,and mechanisms of surface localization.Int J Biochem Cell Biol.2008;40(6-7):1246-72.
13 Carmeliet P,Moons L,Dewerchin M et al.Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998;140(1):233-45.
14.Menshikov M,Elizarova E,Plakida K et al.Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis.Biochem J.2002;367(Pt 3):833-9.
15.Carlin SM,Resink TJ,Tamm M et al.Urokinase signal transduction and its role in cell migration.FASEB J.2005;19(2):195-202.
16.Shushakova N,Eden G,Dangers M et al.The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung.J Immunol.2005;175(6):4060-8.
17.Gyetko MR,Aizenberg D,Mayo-Bond L.Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro.J Leukoc Biol.2004;76(3):648-56.
18.Sitrin RG,Shollenberger SB,Strieter RM et al.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
19.J,Du X,Witte DP,Jirouskova M et al.Leukocyte engagement of fibrin(ogen)via the integrin receptor alphaMbeta2/Mac-l is critical for host inflammatory response in vivo.J Clin Invest.2004;113(11):1596-606.
20.Smiley ST,King JA,Hancock WW.Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4.J Immunol.2001;167(5):2887-94.
21.Lluis F,Roma J,Suelves M et al.Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo.Blood.2001;97(6):1703-11.
22.Lluri G,Jaworski DM.Regulation of TIMP-2,MT1-MMP,and MMP-2 expression during C2C12 differentiation.Muscle Nerve.2005;32(4):492-9.
23.Bryer SC,Fantuzzi G,Van Rooijen N,et al.Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.J Immunol.2008;180(2):1179-88.
24 Binder BR,Mihaly J,Prager GW.uPAR-uPA-PAI-1 interactions and signaling:a vascular biologist's view.Thromb Haemost.2007;97(3):336-42.
25 Sitrin RG,Shollenberger SB,Strieter RM et al.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
26.Rossignol P,Luttun A,Martin-Ventura JL et al.Plasminogen activation:a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.J Thromb Haemost.2006;4(3):664-70.
27 Margaret A.Gyetko,Susan B.Shollenberger,and Robert G.Sitrin.Urokinase expression in mononuclear hagocytesxytokine-specific modulation by interferon-y and tumor necrosis factor-a J.Leukoc.Biol.,1992;31:256-263;
28 St(?)bgen JP.Tumor necrosis factor-alpha antagonists and neuropathy.Muscle Nerve.2008 Mar;37(3):281-92.
29 Feliciani C,Toto P,Wang B,et al.Urokinase plasminogen activator mRNA is induced by IL-1 alpha and TNF-alpha in in vitro acantholysis.Exp Dermatol.2003;12(4):466-71.
30 Ma LJ,Fogo AB.PAI-1 and kidney fibrosis.Front Biosci.2009;14:2028-41.
31 Roelofs JJ,Teske GJ,Bonta PI et al.Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis.Kidney Int.2009;75(1):52-9.Epub 2008 Sep 17.
32.Aso Y.Plasminogen activator inhibitor (PAI)-l in vascular inflammation and thrombosis.Front Biosci.2007;12:2957-66.
33.Andreasen PA.PAI-1-a potential therapeutic target in cancer.Curr Drug Targets.2007;8(9):1030-41.
34 Koh TJ,Bryer SC,Pucci AM et al.Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration.Am J Physiol Cell Physiol.2005;289(1):C217-23.
35 Cao C,Lawrence DA,Li Y et al.Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.EMBO J.2006 3;25(9):1860-70.
36 Czekay RP,Aertgeerts K,Curriden SA et al.Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.J Cell Biol.2003;160(5):781-91.
37.Onwuegbusi BA,Rees JR,Lao-Sirieix P et al.Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.PLoS ONE.2007;2(1):e177.
38 Arndt PG,Young SK,Worthen GS.Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway.J Immunol.2005;175(6):4049-59.
39.Marshall LJ,Ramdin LS,Brooks T et al.Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes.J Immunol.2003;171(4):2057-65.
40.Kwak SH,Wang XQ,He Q et al.Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway.Thromb Haemost.2006;95(5):829-35.
42.Arndt PG,Young SK,Worthen GS.Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway.J Immunol.2005;175(6):4049-59.
43.Balsara RD,Ploplis VA.Plasminogen activator inhibitor-1:the double-edged sword in apoptosis.Thromb Haemost.2008;100(6):1029-36.
44.Schneider DJ,Chen Y,Sobel BE.The effect of plasminogen activator inhibitor type 1 on apoptosis.Thromb Haemost.2008;100(6):103 7-40.
45.Lademann UA,R0mer MU.Regulation of programmed cell death by plasminogen activator inhibitor type 1(PAI-1).Thromb Haemost.2008;100(6):1041-6.
46.Park YJ,Liu G,Lome EF et al.PAI-1 inhibits neutrophil efferocytosis.Proc Natl Acad Sci USA.2008;105(33):11784-9.
47.Nagamine Y.Transcriptional regulation of the plasminogen activator inhibitor type 1—with an emphasis on negative regulation.Thromb Haemost.2008;100(6):1007-13.
1.Nagase H,Visse R,Murphy G.Strucrure and function of matrix metalloproteinases and TIMPs.Cardiovasc Res.2006;69(3):562-73.
2.Carmeli E,Moas M,Reznick Az et al.Matrix metalloproteinases and skeletal muscle:a brief review.Muscle Nerve.2004;29(2):191-7.
3.Malla N,SJ0li S,Winberg JO et al.Biological and pathobiological functions of gelatinase dimers and complexes.Connect Tissue Res.2008;49(3):180-4.
4.Nagase H,Woessner JF Jr.Matrix metalloproteinases.J Biol Chem.1999;274(31):21491-4.
5.Birkedal-Hansen H,Moore WG,Bodden MK,et al.Matrix metalloproteinases:a review.Crit Rev Oral Biol Med.1993;4(2):197-250.
6.Ram M,Sherer Y,Shoenfeld Y.Matrix metalloproteinase-9 and autoimmune diseases.J Clin Immunol.2006;26(4):299-307.
7.Balcerzak D,Querengesser L,Dixon WT,Baracos VE.Coordinate expression of matrix-degrading proteinases and their activators and inhibitors in bovine skeletal muscle.J Anim Sci.2001;79(1):94-107.
8.Kim WU,Min SY,Cho ML,et al.Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.Arthritis Res Ther.2005;7(1):R71-9.
9.Muroski ME,Roycik MD,Newcomer RG et al.Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis.Curr Pharm Biotechnol.2008;9(1):34-46.
10.Kieseier BC,Schneider C,Clements JM,et al.Expression of specific matrix metalloproteinases in inflammatory myopathies.Brain.2001;124(Pt 2):341-51.
11.Choi YC,Dalakas MC.Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.Neurology.2000 11;54(1):65-71.
12.Fukushima K,Nakamura A,Ueda H,et al.Activation and localization of matrix metalloproteinase-2 and-9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ).BMC Musculoskelet Disord.2007;8:54.
13.Wiendl H,Hohlfeld R,Kieseier BC.Immunobiology of muscle:advances in understanding an immunological microenvironment.Trends Immunol.2005;26(7):373-80.
14.Delclaux C,Delacourt C,D'Ortho MP,et al.Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane.Am J Respir Cell Mol Biol.1996;14(3):288-95.
15.Tani K,Ogushi F,Shimizu T,et al.Protease-induced leukocyte chemotaxis and activation:roles in host defense and inflammation.J Med Invest.2001;48(3-4):133-41.
16.Gong Y,Hart E,Shchurin A,et al.Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice.J Clin Invest.2008;118(9):3012-24.
17.Mott JD,Werb Z.Regulation of matrix biology by matrix metallopro-teinases.Curr Opin Cell Biol.2004;16(5):558-64.
18.Visse R,Nagase H.Matrix metalloproteinases and tissue inhibitors of metallopro-teinases:structure,function,and biochemistry.Circ Res.2003;92(8):827-39.
19.Stetler-Stevenson WG.Tissue inhibitors of metalloproteinases in cell signaling:metalloproteinase-independent biological activities.Sci Signal.2008;l(27):re6.
20.Fernandez CA,Butterfield C,Jackson G,et al.Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2):loop 6 is a novel angiogenesis inhibitor.J Biol Chem.2003;278(42):40989-95.
21.von Moers A,Zwirner A,Reinhold A,et al.Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and-2 inDuchenne muscular dystrophy.ActaNeuropathol.2005;109(3):285-93.
22.Srivastava AK,Qin X,Wedhas N,et al.Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAKl)-dependent signaling pathway.J Biol Chem.2007;282(48):35113-24.
23.Liu Z,Li N,Diaz LA,Shipley M,et al.Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.J Clin Invest.2005;115(4):879-87.
24.Stetler-Stevenson WG,Seo DW.TIMP-2:an endogenous inhibitor of angiogenesis.Trends Mol Med.2005;11(3):97-103.
25.Stetler-Stevenson WG.The tumor microenvironment:regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2.Cancer Metastasis Rev.2008;27(1):57-66.
26.English JL,Kassiri Z,Koskivirta I,et al.Individual Timp deficiencies differentially impact pro-MMP-2 activation.J Biol Chem.2006;281 (15):10337-46.
27.Bernardo MM,Fridman R.TIMP-2 (tissue inhibitor of metalloproteinase-2)regulates MMP-2 (matrix metalloproteinase-2)activity in the extracellular environm-ent after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.Biochem J.2003 Sep 15;374(Pt 3):739-45.
28.Lluri G,Langlois GD,Soloway PD,et al.Tissue inhibitor of metalloproteinase-2 (TIMP-2)regulates myogenesis and betal integrin expression in vitro.Exp Cell Res.2008;314(1):11-24.
29.Gomez DE,Alonso DF,Yoshiji H,et al.Tissue inhibitors of metalloproteinases:structure,regulation and biological functions.Eur J Cell Biol.1997 Oct;74(2):l 11-22.
30.Murphy AN,Unsworth EJ,Stetler-Stevenson WG.Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation.J Cell Physiol.1993;157(2):351-8.
31.Rao BG.Recent developments in the design of specific Matrix Metalloproteinase inhibitorsaided by structural and computational studies.Curr Pharm Des.2005;l l(3):295-322.
1.Rider LG,Gurley RC,Pandey JP et al.Clinical,serologic,and immunogenetic features of familial idiopathic inflammatory myopathy.Arthritis Rheum.1998;41(4):710-9.
2.Mastaglia FL,Phillips BA.Idiopathic inflammatory myopathies:epidemiology,classification,and diagnostic criteria.Rheum Dis Clin North Am.2002;28(4):723-41.
3.Shamim EA,Rider LG,Miller FW.Update on the genetics of the idiopathic inflammatory myopathies.Curr Opin Rheumatol.2000;12(6):482-91.
4.Dalakas MC.Therapeutic targets in patients with inflammatory myopathies:present approaches and a look to the future.Neuromuscul Disord.2006;16(4):223-36.
5.Labioche I,Liozon E,Weschler B,et al.Refractory polymyositis responding to infliximab:extended follow-up.Rheumatology (Oxford).2004;43(4):531-2.
6.Hengstman G,van den Hoogen FHJ,Van egelen B,et al.Anti-TNF blockade with infliximab(Remicade)in polymyositis and dermatomyositis.Arthritis Rheum,2000;43:s193.
7.Sprott H,Glatzel M,Michel BA.Treatment of myositis with etanercept (Enbrel),a recombinant human solublefusion protein of TNF-alpha type Ⅱ receptor and IgGl.Rheumatology (Oxford).2004;43(4):524-6.
8.Uthman I,El-Sayad J.Refractory polymyositis responding to infliximab.Rheumatology (Oxford).2004;43(9):1198-9.
9.Concstantine K,Saadeh A.Etanercept is effective in treatment of polymyositis/dermatomyositis which is refractory to convestional therapy including steroid and other disease modifying agents.Arthritis Rheum,2000;43:s193
10.Hengstman GJ,van den Hoogen FH,Barrera P et al.Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha:preliminary observations.Eur Neurol.2003;50(1):10-5.
11.Pachman LM,Liotta-Davis MR,Hong DK et al.TNFalpha-308A allele in juvenile dermatomyositis:association with increased production of tumor necrosis factor alpha,disease duration,and pathologic calcifications.Arthritis Rheum.2000;43(10):2368-77.
12.Lutz J,Huwiler KG,Fedczyna T,et al.Increased plasma thrombospondin-1(TSP-1)levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis.Clin Immunol.2002;103(3Pt1):260-3.
13.刘继峰,许爱娥,杜晓航等.肿瘤坏死因子基因多态性与多发性肌炎与皮肌炎的相关性分析.中华风湿病学杂志,2005,9(7):397-400.
14 Royuela M,Rodr(?)guez-Berriguete G,Fraile B et al.TNF-alpha/IL-1/NFkappaB transduction pathway in human cancer prostate.Histol Histopathol.2008;23(10):1279-90.
15.Popa C,Netea MG,van Riel PL,et al.The role of TNF-alpha in chronic inflammatory conditions,intermediary metabolism,and cardiovascular risk.J Lipid Res.2007;48(4):751-62.
16 Ackermann C,Kavanaugh A.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Expert Opin Ther Targets.2007;11(11):1369-84.
17.Efthimiou P.Tumor necrosis factor-alpha in inflammatory myopathies:pathophy-siology and therapeutic implications.Semin Arthritis Rheum.2006;36(3):168-72.
18.Kuru S,Inukai A,Kato T,Liang Yet al.Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and noninflammatory myopathies.Acta Neuropathol.2003;105(3):217-24.
19 Kuru S,Inukai A,Liang Y,Doyu M et al.Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis.Acta Neuropathol.2000;99(5):585-8.
20.Tateyama M,Nagano I,Yoshioka Met al.Expression of tumor necrosis factor-alpha in muscles of polymyositis.J Neurol Sci.1997;146(1):45-51.
21 Gyetko MR,Shollenberger SB,Sitrin RG.Urokinase expression in mononuclear phagocytes:cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.J Leukoc Biol.1992;51(3):256-63.
22 Stubgen JP.Tumor necrosis factor-alpha antagonists and neuropathy.Muscle Nerve.2008;37(3):281-92.
23 Feliciani C,Toto P,Wang B et al.Urokinase plasminogen activator mRNA is induced by IL-1 alpha and TNF-alpha in in vitro acantholysis.Exp Dermatol.2003;12(4):466-71.
24.Peiretti F,Bernot D,Lopez S,et al.Modulation of PAI-1 and proMMP-9 syntheses by soluble TNFalpha and its receptors during differentiation of the human monocytic HL-60 cell line.J Cell Physiol.2003;196(2):346-53.
25 Zhou L,Yan C,Gieling RG et al.Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated Kinase-1.BMC Immunol.2009;10(1):15.
26.Yang WL,Godwin AK,Xu XX.Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells:molecular basis linking ovulation and cancer risk.Cancer Res.2004;64(4):1534-40.
27.Kieseier BC,Schneider C,Clements JM et al.Expression of specific matrix metalloproteinases in inflammatory myopathies.Brain.2001;124(Pt 2):341-51.
28 Choi YC,Dalakas MC.Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.Neurology.2000 11;54(1):65-71.
29 Schoser BG,Blottner D,Stuerenburg HJ.Matrix metalloproteinases in inflammatory myopathies:enhanced immunoreactivity near atrophic myofibers.Acta Neurol Scand 2002,105(4):309-313.
30 Malla N,Sjoli S,Winberg JO et al.Biological and pathobiological functions of gelatinase dimers and complexes.Connect Tissue Res.2008;49(3):180-4.
31 Gabay C,Gay-Croisier F,Roux-Lombard P et al.Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis.A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.Arthritis Rheum 1994;37(12):1744-51.
32.Shimizu T,Tomita Y,Son K,Nishinarita S,Sawada S,Horie T.Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.Clin Rheumatol 2000;19(5):352-9.
33 Min JK,Kim YM,Kim SW,et al.TNF-related activation-induced cytokine enhances leukocyte adhesiveness:induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells.J Immunol.2005;175(1):531-40.
34.Moser B,Wolf M,Walz A,et al.Chemokines:multiple levels of leukocyte migration control.Trends Immunol.2004;25(2):75-84.
35.Lykouras D,Sampsonas F,Kaparianos A,et al.Role and pharmacogenomics of TNF-alpha in asthma.Mini Rev Med Chem.2008;8(9):934-42.
36.Phillips T,Leeuwenburgh C.Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction.FASEB J.2005;19(6):668-70.
37.Dirks AJ,Leeuwenburgh C.Tumor necrosis factor alpha signaling in skeletal muscle:effects of age and caloric restriction.J Nutr Biochem.2006;17(8):501-8.
38 Sitrin RG,Shollenberger SB,Strieter RM,Gyetko MR.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
39 Jackson JM.TNF-alpha inhibitors.J.Dermatol Ther.2007;20(4):251-64.
40 Gao Q,Meijer MJ,Schliiter UG et al.Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and-9 in Crohn's disease.Inflamm Bowel Dis.2007;13(6):693-702.
1.Melchor JP,Strickland S.Tissue plasminogen activator in central nervous system physiology and pathology.Thromb Haemost.2005;93(4):655-60.
2.Killeen S,Hennessey A,El Hassan Y,Waldron B.The urokinase plasminogen activator system in cancer:a putative therapeutic target? Drug News Perspect.2008;21(2):107-16.
3.Li J,Ny A,Leonardsson G,Nandakumar KS et al.The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type Ⅱ-induced arthritis.Am J Pathol.2005;166(3):783-92.
4.Judex MO,Mueller BM.Plasminogen activation/plasmin in rheumatoid arthritis:matrix degradation and more.Am J Pathol.2005;166(3):645-7.
5.Crippa MP.Urokinase-type plasminogen activator.Int J Biochem Cell Biol.2007;39(4):690-4.
6.Tang CH,Wei Y.The urokinase receptor and integrins in cancer progression.Cell Mol Life Sci.2008;65(12):1916-32.
7.Vassalli JD,Sappino AP,Belin D.The plasminogen activator/plasmin system.J Clin Invest.1991;88(4):1067-72.
8.Owen CA.Leukocyte cell surface proteinases:regulation of expression,functions,and mechanisms of surface localization.Int J Biochem Cell Biol.2008;40(6-7):1246-72.
9 Carmeliet P,Moons L,Dewerchin M,et al.Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998;140(1):233-45.
10.Liu Z,Li N,Diaz LA,et al.Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.J Clin Invest.2005;115(4):879-87.
11.Binder BR,Mihaly J,Prager GW.uPAR-uPA-PAI-1 interactions and signaling:a vascular biologist's view.Thromb Haemost.2007;97(3):336-42.
12.Carmeliet P,Moons L,Dewerchin M et al.Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998 12;140(1):233-45.
13.Rossignol P,Luttun A,Martin-Ventura JL et al.Plasminogen activation:a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.J Thromb Haemost.2006;4(3):664-70.
14.Horowitz JC,Rogers DS,Simon RH et al.Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis.Am J Respir Cell Mol Biol.2008;38(1):78-87.
15.Carlin SM,Resink TJ,Tamm M,et al.Urokinase signal transduction and its role in cell migration.FASEB J.2005;19(2):195-202.
16.Bryer SC,Fantuzzi G,Van Rooijen N et al.Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.J Immunol.2008;180(2):1179-88.
17 Gyetko MR,Aizenberg D,Mayo-Bond L.Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro.J Leukoc Biol.2004;76(3):648-56.
18.Sitrin RG,Shollenberger SB,Strieter RM et al.Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.J Leukoc Biol.1996;59(2):302-11.
19.Shushakova N,Eden G,Dangers M et al.The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung.J Immunol.2005;175(6):4060-8.
20.Hoyer-Hansen G,Lund IK.Urokinase receptor variants in tissue and body fluids.Adv Clin Chem.2007;44:65-102.
21.Plesner T,Behrendt N,Ploug M.Structure,function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor,uPAR.Stem Cells.1997;15(6):398-408.
22 Llinas P,Le Du MH,Gardsvoll H et al.Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.EMBO J.2005 4;24(9):1655-63.
23.Olson LJ,Yammani RD,Dahms NM et al.Structure of uPAR,plasminogen,and sugar-binding sites of the 300 kDa mannose 6-phosphate receptor.EMBO J.2004;23(10):2019-28.
24 Roelofs J J,Teske GJ,Bonta PI et al.Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis.Kidney Int.2009;75(1):52-9.
25.Cao C,Lawrence DA,Li Y et al.Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.EMBO J.2006;25(9):1860-70.
26.Cale JM,Lawrence DA.Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.Curr Drug Targets.2007;8(9):971-81.
27.Marshall LJ,Ramdin LS,Brooks T et al.Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes.J Immunol.2003;171(4):2057-65.
28.Kwak SH,Wang XQ,He Q et al.Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway.Thromb Haemost.2006;95(5):829-35.
29.Degryse B,Neels JG,Czekay RP et al.The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.J Biol Chem.2004;279(21):22595-604.
30 Arndt PG,Young SK,Worthen GS.Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway.J Immunol.2005;175(6):4049-59.
31.Balsara RD,Ploplis VA.Plasminogen activator inhibitor-1:the double-edged sword in apoptosis.Thromb Haemost.2008;100(6):1029-36.
32.Schneider DJ,Chen Y,Sobel BE.The effect of plasminogen activator inhibitor type 1 on apoptosis.Thromb Haemost.2008;100(6):1037-40.
33.Lademann UA,Romer MU.Regulation of programmed cell death by plasminogen activator inhibitor type l(PAI-l).Thromb Haemost.2008;100(6).T041-6.
[1].Hugues,S.M.,and Blau,H.M.Migration of myoblasts across basal lamina during skeletal muscle development.[J].Nature,1990,345:350-353.
[2].Shi,X.,and D.J.Garry.Muscle stem cells in development,regeneration,and disease.Genes Dev.2006.20:1692-1708.
[3].Munoz-Canoves P,Miralles F,Baiget M,and Felez J.Inhibition of urokinase-type plasminogen activator (uPA)abrogates myogenesis in vitro.Thromb Haemost 1997.77:526-534,
[4].Lluis,F.,J.Roma,M.Suelves,et al.Urokinase-dependentplasminogen activation is required for effi cient skeletal muscle regeneration in vivo.Blood.2001.97:1703-1711.
[5].Lopez-Alemany,R.,Suelve,M.,Munoz-Canoves,P.Plasmin generation dependent on a-enolase-type plasminogen receptor is required for myogenesis.Thromb Haemost.2003;90:724-33.
[6].M.Suelves,B.Vidal,A.L.Serrano,et al.uPA deficiency exacerbates muscular dystrophy in MDX mice J.Cell Biol.,September 7,2007;178(6):1039-1051.
[7].Carmeliet,and P.Munoz-Canoves.Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo.Blood.2002.99:2835-2844.
[8].Carmeliet P,Moons L,Dewerchin M.et al.Receptor independent role of urokinase-type activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.J Cell Biol.1998,140:233-245.
[9].Castellino FJ,Ploplis VA.Structure and function of the plasminogen/plasmin system.Thromb Haemost 2005;93:647-654.
[10].Blasi F,Carmeliet P.uPAR:a versatile signaling orchestrator.Nat Rev Mol Cell Biol.2002,3:932-943
[11].Ingber,D.Celluar tensegrity:defining new rules of biological design that govern the cytoskeleton.[J]Cell Sci.1993,104:613-627
[12].Kanse,S.M.,Kost,C.,Wilhelm,O.G.,et al.The urokinase receptor is a major vitronectin-binding protein on endothelial cells.Exp.Cell Res.1996.224:344-353.
[13].Waltz DA,Natkin LR,Fujita RM,Wei Y,and Chapman HA.Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.J Clin Invest.1997.100:58-67,
[14].Chazaud B,Bonavaud S,Plonquet A,et al.Involvement of the [uPAR:uPA:PAI-l:LRP]complex in human myogenic cell motility.Exp Cell Res 2000,258:237-244.
[15].Bonavaud,S.,Charriere-Bertrand,C.,Rey,C.,et al.Evidence of a non-conventional role for the urokinase tripartite complex in myogenic fusion.J.Cell Sci.1997,110:1083-1089
[16]Koh,T.J.,S.C.Bryer,A.M.Pucci,and T.H.Sisson.Mice defi cient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration.Am.J.Physiol.Cell Physiol.2005.289:C217-C223.
[17].Suelves,M.,B.Vidal,V.Ruiz,B.Baeza-Raja,A.Diaz-Ramos,I.Cuartas,F.Lluis,M.Parra,M.Jardi,R.Lopez-Alemany,et al.The plasminogen activation system in skeletal muscle regeneration:antagonistic roles of urokinase-type plasminogen activator (uPA)and its inhibitor (PAI-1).Front.Biosci.2005.10:2978-2985.
[18].Planus,E.,Barlovatz-Meimon,G.,Rogers,R.A.,et al.Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.J.Cell Sci.1997,110:1091-1098
[19]Kjoller,L.,Kanse,S.M.,Kirkegaard,T.,et al.plasminogen activator inhibitor type 1 represses integrin-and vitronectin-mediated cell migration independent of its function as an inhibitor of plasmingen activation.Exp Cell Res 1997,232:420-429.
[20]Tatsumi R,Anderson JE,Nevoret CJ,Halevy O,and Allen RE.HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells.Dev Biol.1998.194:114-128,
[21]Yablonka-Reuveni Z,Seger R,and Rivera AJ.Fibroblast growth factor promotes recruitment of skeletal muscle satellite cells in young and old rats.J Histochem Cytochem.1999.47:23-42,
[22]Mars WM,Zarnegar R,and Michalopoulos GK.Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.Am J Pathol.1993.143:949-958,
[23]Naldini L,Tamagnone L,Vigna E,Sachs M,Hartmann G,Birchmeier W,Daikuhara Y,Tsubouchi H,Blasi F,and Comoglio PM.Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.EMBO J.1992.11:4825-4833,
[24]Fibbi G,D'Alessio S,Pucci M,Cerletti M,and Del Rosso M.Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system.Biol Chem.2002.383:127-136,
[25]Arnold,L.,A.Henry,F.Poron,Y.Baba-Amer,N.van Rooijen,A.Plonquet,R.K.Gherardi,and B.Chazaud.Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis.J.Exp.Med.2007.204:1057-1069.
[26]Tidball,J.G.,and M.Wehling-Henricks.Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo.J.Physiol.2007.578:327-336.
[27]Bryer SC,Fantuzzi G,Van Rooijen N,Koh TJ.Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.J Immunol.2008.180(2):1179-88.
[28]D.M.DiPasquale,M.Cheng,W.Billich,S.A.Huang,N.van Rooijen,T.A.Hornberger,and T.J.Koh.Urokinase-type plasminogen activator and macrophages are required for skeletal muscle hypertrophy in mice.Am J Physiol Cell Physiol,2007;293(4):C1278-C1285.
[29]Sonnet,C,P.Lafuste,L.Arnold,M.Brigitte,F.Poron,F.J.Authier,F.Chretien,R.K.Gherardi,and B.Chazaud.Human macrophages rescue myoblasts and myotubes from apoptosis through a set of adhesion molecular systems.J.Cell Sci.2006.119:2497-2507.
[30]Luikart,S.,M.Masri,D.Wahl,T.Hinkel,J.M.Beck,M.R.Gyetko,P.Gupta,and T.Oegema.Urokinase is required for the formation of mactinin,an alpha-actinin fragment that promotes monocyte/macrophage maturation.Biochim.Biophys.Acta.2002.1591:99-107.
[31]Navaneetha K.Rao,Guo-Ping Shi,Harold A.Urokinase Receptor Is a Multifunctional Protein:Influence of ReceptorOccupancy on Macrophage Gene Expression.J.Clin.Invest.Volume,1995;96:465-474
[32]Margaret R.Gyetko,Robert F.Todd,Camille C.Wilkinson,et al.The Urokinase Receptor Is Required for Human Monocyte Chemotaxis In Vitro.J.Clin.Invest.1994.93:1380-1387.
[33]Scott C.Bryer,Timothy J.Koh.The urokinase-type plasminogen activator receptor is not required for skeletal muscle inflammation or regeneration.Am J Physiol Regul Inter Comp Physiol.2007.293:R1152-1158.
1.Carswell EA,Old LJ,Kassel RL et al.An endotoxin-induced serum factor that causes necrosis of tumors.Proc Natl Acad Sci USA.1975;72(9):3666-70.
2.Medzhitov R,Janeway C Jr.Innate immunity.N Engl J Med.2000 Aug 3;343(5):338-44.
3.Royuela M,Rodriguez-Berriguete G,Fraile B,et al.TNF-alpha/IL-1/NF-κB transduction pathway in human cancer prostate.Histol Histopathol.2008 Oct;23(10):1279-90.
4.Brightling C,Berry M,Amrani Y.Targeting TNF-alpha:a novel therapeutic approach for asthma.J Allergy Clin Immunol.2008;121(1):5-10;quiz 11-2.
5.Mease PJ,Kivitz AJ,Burch FX et al.Etanercept treatment of psoriatic arthritis:safety,efficacy,and effect on disease progression.Arthritis Rheum.2004;50(7):2264-72.
6.Srübgen JP.Tumor necrosis factor-alpha antagonists and neuropathy.Muscle Nerve.2008;37(3):281-92.
7.Sprott H,Glatzel M,Michel BA.Treatment of myositis with etanercept (Enbrel),a recombinant human soluble fusion protein of TNF-alpha type Ⅱ receptor and IgGl.Rheumatology (Oxford).2004;43(4):524-6.
8.Uthman I,El-Sayad J.Refractory polymyositis responding to infliximab.Rheumatology (Oxford).2004;43(9):1198-9.
9.Concstantine K,Saadeh A.Etanercept is effective in treatment of polymyositis/dermatomyositis which is refractory to convestntional therapy including steroid and other disease modifying agents.Arthritis Rheum,2000;43:s193
10.Hengstman GJD,van den Hoogen FHJ,Barrera P et al.Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis.European Neurology;2003;50(1):10-15
11.Cazzola M,Polosa R.Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma.Curr Opin Allergy Clin Immunol.2006;6(1):43-50.
12.Lykouras D,Sampsonas F,Kaparianos A,Karkoulias K et al.Role and pharmacogenomics of TNF-alpha in asthma.Mini Rev Med Chem.2008;8(9):934-42.
13.Popa C,Netea MG,van Riel PL et al.The role of TNF-alpha in chronic inflammatory conditions,intermediary metabolism,and cardiovascular risk.J Lipid Res.2007;48(4):751-62.
14 Ackermann C,Kavanaugh A.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Expert Opin Ther Targets.2007 Nov;11(11):1369-84.
15.Hatano E.Tumor necrosis factor signaling in hepatocyte apoptosis.J Gastroenterol Hepatol.2007;22 Suppl 1:S43-4.
17 Cope A,Ettinger R,McDevitt H.The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire.Res Immunol.1997;148(5):307-12.
18.Cope AP,Liblau RS,Yang XD,Congia M,Laudanna C,Schreiber RD,Probert L,Kollias G,McDevitt HO.Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling.J Exp Med.1997;185(9):1573-84.
19.Hughes G,Murphy MP,Ledgerwood EC.Mitochondrial reactive oxygen species regulate the temporal activation of nuclear factor kappaB to modulate tumour necrosis factor-induced apoptosis:evidence from mitochondria-targeted antioxidants.Biochem J.2005;389(Pt 1):83-9.
20 Li JM,Fan LM,Christie MR et al.Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells:role of p47phox phosphorylation and binding to TRAF4.Mol Cell Biol.2005;25(6):2320-30.
21.Kieseier BC,Kiefer R,Gold R et al.Advances in understanding and treatment of immune-mediated disorders of theperipheral nervous system.Muscle Nerve.2004;30(2):131-56.
22 Min JK,Kim YM,Kim SW et al.TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells.J Immunol.2005;175(1):531-40.
23.Moser B,Wolf M,Walz A et al.Chemokines:multiple levels of leukocyte migration control.Trends Immunol.2004;25(2):75-84.
24.Yang WL,Godwin AK,Xu XX.Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells:molecular basis linking ovulation and cancer risk.Cancer Res.2004;64(4):1534-40.
25.Zhou L,Yan C,Gieling RG et al.Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated Kinase-1.BMC Immunol.2009;10(1):15.
26.Peiretti F,Bernot D,Lopez S,Bonardo B et al.Modulation of PAI-1 and proMMP-9 syntheses by soluble TNFalpha and its receptors during differentiation of the human monocytic HL-60 cell line.J Cell Physiol.2003;196(2):346-53.
27 Feliciani C,Toto P,Wang B et al.Urokinase plasminogen activator mRNA is induced by IL-1 alpha and TNF-alpha in in vitro acantholysis.Exp Dermatol.2003;12(4):466-71.
28.Gyetko MR,Shollenberger SB,Sitrin RG.Urokinase expression in mononuclear phagocytes:cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.J Leukoc Biol.1992;51(3):256-63.
29.Kuru S,Inukai A,Kato T,et al.Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies.Acta Neuropathol,2003,105(3):217-24.
30 Kuru S,Inukai A,Liang Y,et al.Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis.Acta Neuropathol.2000;99(5):585-8.
31.Tateyama M,Nagano I,Yoshioka M,et al.J Neurol Sci.Expression of tumor necrosis factor-alpha in muscles of polymyositis.1997,146(1):45-51.
32.Efthimiou P.Tumor necrosis factor-alpha in inflammatory myopathies:pathophysiology and therapeutic implications.Semin Arthritis Rheum.2006;36(3):168-72.
33 Dirks AJ,Leeuwenburgh C.Tumor necrosis factor alpha signaling in skeletal muscle:effects of age and caloric restriction.J Nutr Biochem.2006;17(8):501-8.
35.Le Magueresse-Battistoni B,Pernod G,Kolodie L et al.Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rattesticular peritubular cells.Endocrinology.1997;138(3):1097-105.
36.Lopez S,Peiretti F,Bonardo B et al.Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells.J Biol Chem.2000;275(5):3081-7.
37.Bauer S,Pollheimer J,Hartmann J et al.Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures.J Clin Endocrinol Metab.2004;89(2):812-22.
38.Park YJ,Liu G,Lome EF et al.PAI-1 inhibits neutrophil efferocytosis.Proc Natl Acad Sci USA.2008;105(33):11784-9.
39.Jackson JM.TNF-alpha inhibitors.J.Dermatol Ther.2007;20(4):251-64.